LIGAND PHARMACEUTICALS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 607,222 | $63,843,321 | 0.92% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 1, 2025 |
| June 30, 2025 | 604,813 | $68,755,142 | 0.91% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 30, 2025 |
| Sept. 30, 2025 | 554,542 | $98,231,570 | 1.27% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Oct. 28, 2025 |
| Dec. 31, 2025 | 501,040 | $94,731,633 | 1.23% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 5, 2026 |
| March 31, 2026 | 494,670 | $98,760,866 | 1.35% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | April 28, 2026 |
| June 30, 2026 | 475,609 | $150,335,249 | 1.61% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 29, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.